Belize vs Senegal: Average cost of multi drug-resistant tuberculosis treatment
Belize
3,017 constant 2022 US$
in 2024
Senegal
3,428 constant 2022 US$
in 2024
Belize rank
15th
Senegal rank
12th
Average cost of multi drug-resistant tuberculosis treatment over time
- Belize
- Senegal
How they compare
Senegal currently reports 3,428 constant 2022 US$ against 3,017 constant 2022 US$ in Belize, a difference of 411 constant 2022 US$.
That makes Senegal's figure about 1.1 times Belize's.
The two have swapped places 3 times across 5 shared years of data; in 2018 it was Belize ahead.
Belize ranks 15th and Senegal ranks 12th of 92 countries.
Across the 2 decades both report, Belize averaged higher in 1 and Senegal in 1.
Head to head by decade
| Decade | Belize | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,160 constant 2022 US$ | 820 constant 2022 US$ | 2,340 constant 2022 US$ | Belize |
| 2020s | 2,000 constant 2022 US$ | 2,913 constant 2022 US$ | 912.5 constant 2022 US$ | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Belize or Senegal?
- Senegal, at 3,428 constant 2022 US$ against 3,017 constant 2022 US$ in Belize as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Belize and Senegal?
- 411 constant 2022 US$, with Senegal ahead.
- How many years of comparable data are there for Belize and Senegal?
- 5 years are reported by both, from 2018 to 2024.
- How do Belize and Senegal rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Belize ranks 15th and Senegal ranks 12th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.